GlassScriptPhysician profile
Hop Duong
NPI 1659664274
$5,929.37
in general payments reported to CMS, 2019-2025
30 companies · $654 in 2025
The $654 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $116 · 2021: $666 · 2022: $1,366 · 2023: $1,570 · 2024: $1,059 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,276 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.24 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,250.85 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $870.85 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.16 | 2020-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $403.70 | 2022-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $397.58 | 2021-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $390.26 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $316.32 | 2022 | |
| Glaxosmithkline, LLC. | $251.93 | 2022-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $218.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.45 | 2023-2025 | |
| Medtronic, INC. | $164.74 | 2021-2025 | Mazor X System |
| Hologic Sales and Service, LLC | $122.53 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.90 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.08 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $76.98 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75.28 | 2024 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $73.13 | 2021 | |
| Scilex Pharmaceuticals INC. | $72.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $56.65 | 2019-2020 | |
| Braeburn INC. | $42.22 | 2024-2025 | Brixadi |
| Paratek Pharmaceuticals, INC. | $30.67 | 2024-2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.90 | 2023-2024 | Relistor |
| Indivior INC. | $28.07 | 2024 | Sublocade |
| Exact Sciences Corporation | $22.81 | 2025 | The Cologuard Plus Collection Kit |
| Ethicon US, LLC | $20.30 | 2019 | |
| Phadia US INC. | $19.99 | 2023 | Immunocap |
| Orexo US, INC. | $16.15 | 2019 | |
| Itamar Medical INC | $15.29 | 2024 | Watchpatone |
| Antares Pharma, INC. | $14.90 | 2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $5.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hop Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.